-MedGuardian to be Integrated into Pharmacy Data Collection, Analysis and Solution Firm-
NEW YORK–(BUSINESS WIRE)–Healthnostics, Inc., a medical and biotechnology analytics company, today announced the acquisition of privately-held MedTrec, Inc., a pharmacy data collection firm.
Healthnostics will merge its MedGuardian hospital systems development and marketing operations into MedTrec, Inc., utilizing its proprietary PharmaX pharmacy data collection system. MedTrec will operate as a wholly-owned subsidiary of Healthnostics.
MedTrec’s lead product PharmaX is much more than a run-of-the-mill pharmacy data collection system. PharmaX provides clinical level accuracy. It is interactive, real-time and not only tracks medications provided to patients in clinical and non-clinical settings, but also possesses a host of abilities not present in today’s market including, but not limited to:
* the ability to track when and/or if a patient has taken their medication;
* the pharmacological indications and contraindications of medications (valuable for both prescribing physicians and patients);
* length of time in which medications can be administered to maintain blood levels necessary for efficacy;
* time stamps, and a host of other “solutions” that are presently not available in today’s marketplace.
“Our relentless efforts in growing our business model to achieve its maximum potential and achieve profitability are most definitively being demonstrated through this strategically viable acquisition,” stated Alan W. Grofe, President.
“We look forward to bringing PharmX to the American Society of Pharmacologists, the medical community in totality, and consumers/patients sorely in need of this type of information and service,” Grofe concluded.
About Healthnostics
Healthnostics, Inc. is a medical and biotechnology analytics company that provides patient clinical monitoring and risk management systems to acute care hospitals, and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld(tm), one of the largest professional medical and biotechnology resource and reference portal sites on the Internet, MedNets.com healthcare professional and consumer portal, and FamilyMedicalNet, a consumer healthcare information portal.
For further information regarding Healthnostics, please visit Healthnostics (www.healthnostics.com), MedGuardian (www.med-guardian.com), MedBioWorld (www.medbioworld.com), and FamilyMedicalNet (www.familymedicalnet.com), MedNets (www.mednets.com).
This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.
Contact:
for Healthnostics, Inc.
Cynthia DeMonte, 917-273-1717
cynthiademonte@gmail.com
Source: Healthnostics, Inc.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC expects to be compensated as much at $12,300 for profile coverage from StockPromoters.com. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
